Cargando…
Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis
One of the target drugs for plaque psoriasis treatment is apremilast, which is a selective phosphodiesterase 4 (PDE4) inhibitor. In this study, 34 moderate-to-severe and severe plaque psoriasis patients from Russia were treated with apremilast for 26 weeks. This allowed us to observe the effectivene...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823747/ https://www.ncbi.nlm.nih.gov/pubmed/33383665 http://dx.doi.org/10.3390/jpm11010020 |
_version_ | 1783639909610815488 |
---|---|
author | Verbenko, Dmitry A. Karamova, Arfenya E. Artamonova, Olga G. Deryabin, Dmitry G. Rakitko, Alexander Chernitsov, Alexandr Krasnenko, Anna Elmuratov, Artem Solomka, Victoria S. Kubanov, Alexey A. |
author_facet | Verbenko, Dmitry A. Karamova, Arfenya E. Artamonova, Olga G. Deryabin, Dmitry G. Rakitko, Alexander Chernitsov, Alexandr Krasnenko, Anna Elmuratov, Artem Solomka, Victoria S. Kubanov, Alexey A. |
author_sort | Verbenko, Dmitry A. |
collection | PubMed |
description | One of the target drugs for plaque psoriasis treatment is apremilast, which is a selective phosphodiesterase 4 (PDE4) inhibitor. In this study, 34 moderate-to-severe and severe plaque psoriasis patients from Russia were treated with apremilast for 26 weeks. This allowed us to observe the effectiveness of splitting patient cohorts based on clinical outcomes, which were assessed using the Psoriasis Area Severity Index (PASI). In total, 14 patients (41%) indicated having an advanced outcome with delta PASI 75 after treatment; 20 patients indicated having moderate or no effects. Genome variability was investigated using the Illumina Infinium Global Screening Array. Genome-wide analysis revealed apremilast therapy clinical outcome associations at three compact genome regions with undefined functions situated on chromosomes 2, 4, and 5, as well as on a single single-nucleotide polymorphism (SNP) on chromosome 23. Pre-selected SNP sets were associated with psoriasis vulgaris analysis, which was used to identify four SNP-associated targeted therapy efficiencies: IL1β (rs1143633), IL4 (IL13) (rs20541), IL23R (rs2201841), and TNFα (rs1800629) genes. Moreover, we showed that the use of the global polygenic risk score allowed for the prediction of onset psoriasis in Russians. Therefore, these results can serve as a starting point for creating a predictive model of apremilast therapy response in the targeted therapy of patients with psoriasis vulgaris. |
format | Online Article Text |
id | pubmed-7823747 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-78237472021-01-24 Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis Verbenko, Dmitry A. Karamova, Arfenya E. Artamonova, Olga G. Deryabin, Dmitry G. Rakitko, Alexander Chernitsov, Alexandr Krasnenko, Anna Elmuratov, Artem Solomka, Victoria S. Kubanov, Alexey A. J Pers Med Article One of the target drugs for plaque psoriasis treatment is apremilast, which is a selective phosphodiesterase 4 (PDE4) inhibitor. In this study, 34 moderate-to-severe and severe plaque psoriasis patients from Russia were treated with apremilast for 26 weeks. This allowed us to observe the effectiveness of splitting patient cohorts based on clinical outcomes, which were assessed using the Psoriasis Area Severity Index (PASI). In total, 14 patients (41%) indicated having an advanced outcome with delta PASI 75 after treatment; 20 patients indicated having moderate or no effects. Genome variability was investigated using the Illumina Infinium Global Screening Array. Genome-wide analysis revealed apremilast therapy clinical outcome associations at three compact genome regions with undefined functions situated on chromosomes 2, 4, and 5, as well as on a single single-nucleotide polymorphism (SNP) on chromosome 23. Pre-selected SNP sets were associated with psoriasis vulgaris analysis, which was used to identify four SNP-associated targeted therapy efficiencies: IL1β (rs1143633), IL4 (IL13) (rs20541), IL23R (rs2201841), and TNFα (rs1800629) genes. Moreover, we showed that the use of the global polygenic risk score allowed for the prediction of onset psoriasis in Russians. Therefore, these results can serve as a starting point for creating a predictive model of apremilast therapy response in the targeted therapy of patients with psoriasis vulgaris. MDPI 2020-12-29 /pmc/articles/PMC7823747/ /pubmed/33383665 http://dx.doi.org/10.3390/jpm11010020 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Verbenko, Dmitry A. Karamova, Arfenya E. Artamonova, Olga G. Deryabin, Dmitry G. Rakitko, Alexander Chernitsov, Alexandr Krasnenko, Anna Elmuratov, Artem Solomka, Victoria S. Kubanov, Alexey A. Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis |
title | Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis |
title_full | Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis |
title_fullStr | Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis |
title_full_unstemmed | Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis |
title_short | Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis |
title_sort | apremilast pharmacogenomics in russian patients with moderate-to-severe and severe psoriasis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823747/ https://www.ncbi.nlm.nih.gov/pubmed/33383665 http://dx.doi.org/10.3390/jpm11010020 |
work_keys_str_mv | AT verbenkodmitrya apremilastpharmacogenomicsinrussianpatientswithmoderatetosevereandseverepsoriasis AT karamovaarfenyae apremilastpharmacogenomicsinrussianpatientswithmoderatetosevereandseverepsoriasis AT artamonovaolgag apremilastpharmacogenomicsinrussianpatientswithmoderatetosevereandseverepsoriasis AT deryabindmitryg apremilastpharmacogenomicsinrussianpatientswithmoderatetosevereandseverepsoriasis AT rakitkoalexander apremilastpharmacogenomicsinrussianpatientswithmoderatetosevereandseverepsoriasis AT chernitsovalexandr apremilastpharmacogenomicsinrussianpatientswithmoderatetosevereandseverepsoriasis AT krasnenkoanna apremilastpharmacogenomicsinrussianpatientswithmoderatetosevereandseverepsoriasis AT elmuratovartem apremilastpharmacogenomicsinrussianpatientswithmoderatetosevereandseverepsoriasis AT solomkavictorias apremilastpharmacogenomicsinrussianpatientswithmoderatetosevereandseverepsoriasis AT kubanovalexeya apremilastpharmacogenomicsinrussianpatientswithmoderatetosevereandseverepsoriasis |